HEOR FELLOWSHIP PROGRAM

- 2 -

- 3 -

The University of Washington and Genentech have established a Health Economics and Outcomes Research (HEOR) Fellowship Program. This two-year program will provide formal training and hands-on experience in the HEOR field.

The first year of the program will be spent at the University of Washington (Seattle, WA).

• The fellow will take core courses in biostatistics, health economics, outcomes research, policy, and epidemiology.

• The fellow will be awarded a Master’s Degree from the University upon completion of course requirements and a thesis project.

The second year will be spent at Genentech (South San Francisco, CA)

• The fellow will pursue hands-on training in strategically focused health economics and outcomes to support commercialization of Genentech’s products.

• The fellow will work closely with colleagues in the Evidence for Access organization, which is comprised of HEOR and Health Systems Researchers, in Genentech’s US Medical Affairs organization.

About the Program

David Veenstra, Pharm.D., Ph.D.,Professor and Associate DirectorThe Comparative Health Outcomes, Policy & Economics (CHOICE) Institute1959 NE Pacific Ave., H-375-PSeattle, WA, 98195-7630veenstra@uw.edu

Fellowship DirectorsProgram Information: https://sop.washington.edu/choice

Jennifer Whiteley, EdD, MSc., MATeam Lead, HEOR1 DNA WaySouth San Francisco, CA, 94080whiteley.jennifer@gene.com

- 4 -

About The University of Washington

The University of Washington is a world-class leader in health sciences education and has been consistently listed in US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly noted for its strong research programs and since 1974 has received more federal funds for research and training than any other public university in the United States. It fosters a highly collegial atmosphere between departments and academic units, creating a particularly attractive environment for such partnerships between the public and private sectors.

The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute is housed within the University of Washington School of Pharmacy, which boasts nearly 125 years of academic and research success. Faculty in the program (1) provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs, MDs); (2) conduct rigorous scientific research in economic evaluations and outcomes of pharmaceuticals and other health technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with the goal of improving patient care.

CHOICE faculty participating in the fellowship have been chosen both for their dedication to teaching and their excellence in research. Each is trained either as a health economist or health services researcher and all have an extensive history of effective economic evaluations and pharmacoepidemiologic research.

University of Washington Program Faculty

Anirban Basu, PhDProfessor and Stergachis Family Endowed Director of CHOICE

Denise Boudreau, PhDAffiliate ProfessorKaiser Washington

Beth Devine, PharmD, MBA, PhD, FASHPProfessor, Director of Graduate Programs

Josh Carlson, MPH, PhDAssociate Professor

Louis P. Garrison, Jr., PhDProfessor Emeritus

Ryan Hansen, PhD, PharmDAssistant Professor

Thomas K. Hazlet, PharmD, Dr. PHAssociate Professor

Scott D. Ramsey, MD, PhDProfessor

Sean D. Sullivan, BPharm, PhDProfessor and Dean of School of Pharmacy

David L. Veenstra, PharmD, PhDProfessor and Associate Director of CHOICE

Joseph Babigumira, MBChB, MS, PhDAdjunct Associate Professor

Aasthaa Bansal, PhDAssistant Professor

Caroline Bennette, MPH, PhDAffiliate Assistant ProfessorFlatiron Health

Andy Stergachis, BPharm, PhDProfessor and Associate Dean for Research, Graduate Programs and New Initiatives

Zachary Marcum, PharmD, PhDAssistant Professor

- 5 -

About Genentech

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years.

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.

Our Purpose

Doing now what patients need nextWe believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients’ lives. We are courageous in both decision and action. And we believe that good business means a better world.

That is why we come to work each day. We commit ourselves to scientific rigor, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow.

We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.

Vice PresidentJan Hansen

OperationsEmily Cook

HEORJennifer Whiteley

Health Policy & Systems Research

Danny Yeh

HEORElaine Yu

HEORJim Zazzali

Pictured above: HEOR Fellowship Mentors

- 6 -

Genentech Evidence for Access Leadership Team

Recent Manuscripts: • Meyer R, Patel AM, Rattana SK, Quock TP and Mody SH. Prescription Opioid Abuse: A Literature

Review of the Clinical and Economic Burden in the United States. Population Health Management. Dec 2014;17(6):372–387.

• Paris A, Kozma CM, Chow W, Patel AM, Mody SH and Kim MS. Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR. American Health and Drug Benefits. Nov 2013;6(9): 567-75

Anisha Patel, PhD, MS2010-2012Johnson & Johnson / Rutgers University

Recent Manuscripts: • Sadetsky N, Hernandez A, Wallick CJ, McKenna E, Surinach A, Colburn D. Survival Outcomes

in Advanced Melanoma Patients with CNS Metastases in an Older US Population Using SEER-Medicare Database. Submitted to Annals of Oncology

• Wallick CJ, Hansen RH, Campbell J, Kowalski JW, Kiss S, Sullivan SD. Comorbidity and Health Care Resource Use Among Commercially Insured Non-Elderly Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2015; 46(7):774-51 (2015)

• Wallick CJ, Sullivan SD, Hansen RH. The economic burden of diabetic macular edema in a working age and commercially insured population. University of Washington, Master’s thesis. Proquest. (2013)

• Stewart Williams J, Wallick CJ, Byles JE, Doran CE. Assessing patterns of use of cardio-protective polypill component medicines in Australian women. Drugs & Aging, 30(3), 193-203. (2013)

Chris Wallick, PharmD, MS2012-2014University of Washington / Allergan

Publications (manuscripts/abstracts) from Fellowship • Shapouri S, Devine EB, Keyloun KR, Gillard PJ, Sabbatini AK, Bansal A. Predicting Hospitalizations

and Returns to the Emergency Department 30-Days Post Emergency Department Discharge Among Patients with Acute Bacterial Skin and Skin Structure Infections. (In Progress)

• Harrington A, Bonine NG, Caplan EO, Turner RM, Johnson JC, Shapouri S, Suehs BT, York W, Gillard P. Costs among Women Diagnosed with Symptomatic Uterine Fibroids (UF) Compared to Women without UF in a Commercial Population. AMCP Nexus 2018. October 22-25 Orlando, FL.

• Harrington A, Bonine NG, Caplan EO, Turner RM, Johnson JC, Shapouri S, Suehs BT, York W, Gillard P. Contemporary Treatment Utilization in a Commercial Population of Women Newly Diagnosed with Symptomatic Uterine Fibroids (UF). AMCP Nexus 2018. October 22-25 Orlando, FL.

Sheila Shapouri, PharmD, MS2016-2018University of Washington / Allergan

- 7 -

Past Industry HEOR Fellowship Experience in Evidence for Access

“All trademarks mentioned herein are protected by law”.